Stem cell therapies for muscle disorders

Current Opinion in Neurology

Volumn 25, Issue 5, 2012, Pages 597-603

  Tedesco, Francesco S ^a,b   Cossu, Giulio ^a,b  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

cell therapy; diseases of skeletal muscle; muscular dystrophy; myogenic stem progenitor cells

Indexed keywords

CLINICAL TRIAL; CYTOLOGY; HUMAN; MUSCLE DISEASE; MYOBLAST; NONHUMAN; REVIEW; SKELETAL MUSCLE; STEM CELL; STEM CELL TRANSPLANTATION; STRESS INCONTINENCE;

ANIMALS; HUMANS; MUSCLE CELLS; MUSCULAR DISEASES; MYOBLASTS; PLURIPOTENT STEM CELLS; STEM CELL TRANSPLANTATION;

EID: 84866336634     PISSN: 13507540     EISSN: 14736551     Source Type: Journal    
DOI: 10.1097/WCO.0b013e328357f288     Document Type: Review

References (77)

1. Baron F, Storb R, Little MT. Hematopoietic cell transplantation: five decades of progress. Arch Med Res 2003; 34:528-544. (Pubitemid 38084707)
2. De Luca M, Pellegrini G, Green H. Regeneration of squamous epithelia from stem cells of cultured grafts. Regen Med 2006; 1:45-57.
3. Bernstein HS, Srivastava D. Stem cell therapy for cardiac disease. Pediatr Res 2012; 71 (4 Pt 2):491-499.
4. Ptaszek LM, Mansour M, Ruskin JN, Chien KR. Towards regenerative therapy for cardiac disease. Lancet 2012; 379:933-942.
5. Klumpp D, Horch RE, Kneser U, Beier JP. Engineering skeletal muscle tissue: new perspectives in vitro and in vivo. J Cell Mol Med 2010; 14:2622-2629.
6. Emery AE. The muscular dystrophies. Lancet 2002; 359:687-695. (Pubitemid 34203773)
7. Emery AE, Muntoni F. Duchenne muscular dystrophy.Oxford University Press; Oxford, UK. 2003.
8. Muntoni F, Torelli S, Ferlini A. Dystrophin and mutations: one gene, several proteins, multiple phenotypes. Lancet Neurol 2003; 2:731-740. (Pubitemid 37443515)
9. Davies KE, Nowak KJ. Molecular mechanisms of muscular dystrophies: old and new players. Nat Rev Mol Cell Biol 2006; 7:762-773. (Pubitemid 44450460)
10. Mauro A. Satellite cell of skeletal muscle fibers. J Biophys Biochem Cytol 1961; 9:493-495.
11. Sacco A, Mourkioti F, Tran R, et al. Short telomeres and stem cell exhaustion model Duchenne muscular dystrophy in mdx/mtr mice. Cell 2010; 143: 1059-1071.
12. Cassano M, Dellavalle A, Tedesco FS, et al. Alpha sarcoglycan is required for fgf-dependent myogenic progenitor cell proliferation in vitro and in vivo. Development 2011; 138:4523-4533.
13. Tedesco FS, Dellavalle A, Diaz-Manera J, et al. Repairing skeletal muscle: regenerative potential of skeletal muscle stem cells. J Clin Invest 2010; 120:11-19.
14. Cossu G, Sampaolesi M. New therapies for Duchenne muscular dystrophy: challenges, prospects and clinical trials. Trends Mol Med 2007; 13:520-526. (Pubitemid 350130348)
15. Ferrari G, Cusella-De Angelis G, Coletta M, et al. Muscle regeneration by bone marrow-derived myogenic progenitors. Science 1998; 279:1528-1530. (Pubitemid 28217075)
16. Jones DL, Rando TA. Emerging models and paradigms for stem cell ageing. Nat Cell Biol 2011; 13:506-512.
17. Partridge TA, Morgan JE, Coulton GR, et al. Conversion of mdx myofibres from dystrophin-negative to-positive by injection of normal myoblasts. Nature 1989; 337:176-179. (Pubitemid 19025378)
18. Partridge T. The current status of myoblast transfer. Neurol Sci 2000; 21 (5 Suppl):S939-S942. (Pubitemid 33621624)
19. Montarras D, Morgan J, Collins C, et al. Direct isolation of satellite cells for skeletal muscle regeneration. Science 2005; 309:2064-2067. (Pubitemid 41362326)
20. Gilbert PM, Havenstrite KL, Magnusson KE, et al. Substrate elasticity regulates skeletal muscle stem cell self-renewal in culture. Science 2010; 329:1078-1081.
21. Palmieri B, Tremblay JP, Daniele L. Past, present and future of myoblast transplantation in the treatment of Duchenne muscular dystrophy. Pediatr Transplant 2010; 14:813-819.
22. Perie S, Mamchaoui K, Mouly V, et al. Premature proliferative arrest of cricopharyngeal myoblasts in oculo-pharyngeal muscular dystrophy: therapeutic perspectives of autologous myoblast transplantation. Neuromuscul Disord 2006; 16:770-781. (Pubitemid 44646861)
23. Smaldone MC, Chancellor MB. Muscle derived stem cell therapy for stress urinary incontinence. World J Urol 2008; 26:327-332.
24. Wang HJ, Chuang YC, Chancellor MB. Development of cellular therapy for the treatment of stress urinary incontinence. Int Urogynecol J 2011; 22:1075-1083.
25. Frudinger A, Kolle D, Schwaiger W, et al. Muscle-derived cell injection to treat anal incontinence due to obstetric trauma: Pilot study with 1 year follow-up. Gut 2010; 59:55-61.
26. Cerletti M, Jurga S, Witczak CA, et al. Highly efficient, functional engraftment of skeletal muscle stem cells in dystrophic muscles. Cell 2008; 134:37-47. (Pubitemid 351905744)
27. Sacco A, Doyonnas R, Kraft P, et al. Self-renewal and expansion of single transplanted muscle stem cells. Nature 2008; 456:502-506. (Pubitemid 50278031)
28. Rocheteau P, Gayraud-Morel B, Siegl-Cachedenier I, et al. A subpopulation of adult skeletal muscle stem cells retains all template DNA strands after cell division. Cell 2012; 148:112-125.
29. Ono Y, Masuda S, Nam HS, et al. Slow-dividing satellite cells retain longterm self-renewal ability in adult muscle. J Cell Sci 2012; 125 (Pt 5):1309-1317.
30. Sambasivan R, Yao R, Kissenpfennig A, et al. Pax7-expressing satellite cells are indispensable for adult skeletal muscle regeneration. Development 2011; 138:3647-3656.
31. Murphy MM, Lawson JA, Mathew SJ, et al. Satellite cells, connective tissue fibroblasts and their interactions are crucial for muscle regeneration. Development 2011; 138:3625-3637.
32. Lepper C, Partridge TA, Fan CM. An absolute requirement for pax7-positive satellite cells in acute injury-induced skeletal muscle regeneration. Development 2011; 138:3639-3646.
33. Dellavalle A, Maroli G, Covarello D, et al. Pericytes resident in postnatal skeletal muscle differentiate into muscle fibres and generate satellite cells. Nat Commun 2011; 2:499.
34. Boutet SC, Cheung TH, Quach NL, et al. Alternative polyadenylation mediates microRNA regulation of muscle stem cell function. Cell Stem Cell 2012; 10:327-336.
35. Cheung TH, Quach NL, Charville GW, et al. Maintenance of muscle stem-cell quiescence by microRNA-489. Nature 2012; 482:524-528.
36. Cesana M, Cacchiarelli D, Legnini I, et al. A long noncoding RNA controls muscle differentiation by functioning as a competing endogenous RNA. Cell 2011; 147:358-369.
37. Cabianca DS, Casa V, Bodega B, et al. A long ncRNA links copy number variation to a polycomb/trithorax epigenetic switch in FSHD muscular dystrophy. Cell 2012; 149:819-831.
38. Statland JM, Tawil R. Facioscapulohumeral muscular dystrophy: molecular pathological advances and future directions. Curr Opin Neurol 2011; 24:423-428.
39. Palacios D, Mozzetta C, Consalvi S, et al. Tnf/p38alpha/polycomb signaling to pax7 locus in satellite cells links inflammation to the epigenetic control of muscle regeneration. Cell Stem Cell 2010; 7:455-469.
40. Bjornson CR, Cheung TH, Liu L, et al. Notch signaling is necessary to maintain quiescence in adult muscle stem cells. Stem Cells 2012; 30:232-242.
41. Mourikis P, Sambasivan R, Castel D, et al. A critical requirement for notch signaling in maintenance of the quiescent skeletal muscle stem cell state. Stem Cells 2012; 30:243-252.
42. Wang YX, Rudnicki MA. Satellite cells, the engines of muscle repair. Nat Rev Mol Cell Biol 2012; 13:127-133.
43. Mendell JR, Campbell K, Rodino-Klapac L, et al. Dystrophin immunity in Duchenne's muscular dystrophy. N Engl J Med 2010; 363:1429-1437.
44. Tedesco FS, Hoshiya H, D'Antona G, et al. Stem cell-mediated transfer of a human artificial chromosome ameliorates muscular dystrophy. Sci Transl Med 2011; 3:96-78.
45. Decary S, Mouly V, Hamida CB, et al. Replicative potential and telomere length in human skeletal muscle: Implications for satellite cell-mediated gene therapy. Hum Gene Ther 1997; 8:1429-1438. (Pubitemid 27393998)
46. Lattanzi L, Salvatori G, Coletta M, et al. High efficiency myogenic conversion of human fibroblasts by adenoviral vector-mediated MyoD gene transfer. An alternative strategy for ex vivo gene therapy of primary myopathies. J Clin Invest 1998; 101:2119-2128. (Pubitemid 28244096)
47. Berghella L, De Angelis L, Coletta M, et al. Reversible immortalization of human myogenic cells by site-specific excision of a retrovirally transferred oncogene. Hum Gene Ther 1999; 10:1607-1617. (Pubitemid 29328205)
48. Kimura E, Han JJ, Li S, et al. Cell-lineage regulated myogenesis for dystrophin replacement: a novel therapeutic approach for treatment of muscular dystrophy. Hum Mol Genet 2008; 17:2507-2517.
49. Muses S, Morgan JE, Wells DJ. Restoration of dystrophin expression using the sleeping beauty transposon. PLoS Curr 2011; 3:RRN1296.
50. Mitchell KJ, Pannerec A, Cadot B, et al. Identification and characterization of a nonsatellite cell muscle resident progenitor during postnatal development. Nat Cell Biol 2010; 12:257-266.
51. Parker MH, Kuhr C, Tapscott SJ, Storb R. Hematopoietic cell transplantation provides an immune-tolerant platform for myoblast transplantation in dystrophic dogs. Mol Ther 2008; 16:1340-1346. (Pubitemid 351866067)
52. Rouger K, Larcher T, Dubreil L, et al. Systemic delivery of allogenic muscle stem cells induces long-term muscle repair and clinical efficacy in Duchenne muscular dystrophy dogs. Am J Pathol 2011; 179:2501-2518.
53. Piccoli M, Franzin C, Bertin E, et al. Amniotic fluid stem cells restore the muscle cell niche in a HSA-Cre, Smn (F7/F7) mouse model. Stem Cells 2012; 1675-1684.
54. Minasi MG, Riminucci M, De Angelis L, et al. The meso-angioblast: a multipotent, self-renewing cell that originates from the dorsal aorta and differentiates into most mesodermal tissues. Development 2002; 129: 2773-2783. (Pubitemid 34874259)
55. Sampaolesi M, Torrente Y, Innocenzi A, et al. Cell therapy of alpha-sarcoglycan null dystrophic mice through intra-arterial delivery of mesoangioblasts. Science 2003; 301:487-492. (Pubitemid 36900300)
56. Diaz-Manera J, Touvier T, Dellavalle A, et al. Partial dysferlin reconstitution by adult murine mesoangioblasts is sufficient for full functional recovery in a murine model of dysferlinopathy. Cell Death Dis 2010; 1:e61.
57. Berry SE, Liu J, Chaney EJ, Kaufman SJ. Multipotential mesoangioblast stem cell therapy in the mdx/utrn-/-mouse model for Duchenne muscular dystrophy. Regen Med 2007; 2:275-288. (Pubitemid 46845886)
58. Sampaolesi M, Blot S, D'Antona G, et al. Mesoangioblast stem cells ameliorate muscle function in dystrophic dogs. Nature 2006; 444:574-579. (Pubitemid 44864430)
59. Dellavalle A, Sampaolesi M, Tonlorenzi R, et al. Pericytes of human skeletal muscle are myogenic precursors distinct from satellite cells. Nat Cell Biol 2007; 9:255-267. (Pubitemid 46349927)
60. Yamanaka S. A fresh look at iPS cells. Cell 2009; 137:13-17.
61. Wu SM, Hochedlinger K. Harnessing the potential of induced pluripotent stem cells for regenerative medicine. Nat Cell Biol 2011; 13:734.
62. Nishikawa S, Goldstein RA, Nierras CR. The promise of human induced pluripotent stem cells for research and therapy. Nat Rev Mol Cell Biol 2008; 9:725-729.
63. Chang H, Yoshimoto M, Umeda K, et al. Generation of transplantable, functional satellite-like cells from mouse embryonic stem cells. FASEB J 2009; 23:1907-1919.
64. Mizuno Y, Chang H, Umeda K, et al. Generation of skeletal muscle stem/progenitor cells from murine induced pluripotent stem cells. FASEB J 2010; 24:2245-2253.
65. Barberi T, Bradbury M, Dincer Z, et al. Derivation of engraftable skeletal myoblasts from human embryonic stem cells. Nat Med 2007; 13:642-648. (Pubitemid 46828477)
66. Sakurai H, Okawa Y, Inami Y, et al. Paraxial mesodermal progenitors derived from mouse embryonic stem cells contribute to muscle regeneration via differentiation into muscle satellite cells. Stem Cells 2008; 26:1865-1873.
67. Darabi R, Gehlbach K, Bachoo RM, et al. Functional skeletal muscle regeneration from differentiating embryonic stem cells. Nat Med 2008; 14:134-143. (Pubitemid 351214552)
68. Darabi R, Pan W, Bosnakovski D, et al. Functional myogenic engraftment from mouse iPS cells. Stem Cell Rev 2011; 7:948-957.
69. Quattrocelli M, Palazzolo G, Floris G, et al. Intrinsic cell memory reinforces myogenic commitment of pericyte-derived iPSCs. J Pathol 2011; 223:593-603.
70. Darabi R, Santos FN, Filareto A, et al. Assessment of the myogenic stem cell compartment following transplantation of pax3/pax7-induced embryonic stem cell-derived progenitors. Stem Cells 2011; 29:777-790.
71. Darabi R, Arpke RW, Irion S, et al. Human ES-and iPS-derived myogenic progenitors restore dystrophin and improve contractility upon transplantation in dystrophic mice. Cell Stem Cell 2012; 10:610-619.
72. Dar A, Domev H, Ben-Yosef O, et al. Multipotent vasculogenic pericytes from human pluripotent stem cells promote recovery of murine ischemic limb. Circulation 2012; 125:87-99.
73. Lian Q, Zhang Y, Zhang J, et al. Functional mesenchymal stem cells derived from human induced pluripotent stem cells attenuate limb ischemia in mice. Circulation 2010; 121:1113-1123.
74. Tedesco FS, Gerli MF, Perani L, et al. Transplantation of genetically corrected human iPSC-derived progenitors in mice with limb-girdle muscular dystrophy. Sci Transl Med 2012; 4:140-189.
75. Kazuki Y, Hiratsuka M, Takiguchi M, et al. Complete genetic correction of iPS cells from Duchenne muscular dystrophy. Mol Ther 2010; 18:386-393.
76. Maherali N, Hochedlinger K. Guidelines and techniques for the generation of induced pluripotent stem cells. Cell Stem Cell 2008; 3:595-605.
77. Partridge TA. Impending therapies for Duchenne muscular dystrophy. Curr Opin Neurol 2011; 24:415-422.